Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sherene Loi

Showing results (131-140 of 325) with videos related to

Pageof 33
Sort By:
Cancer Research|September 1, 2017
CD73 Promotes Resistance to HER2/ErbB2 Antibody TherapyMartin Turcotte, David Allard, Deepak Mittal, et al.
Breast Cancer Research : BCR|August 15, 2019
Neoadjuvant neratinib promotes ferroptosis and inhibits brain metastasis in a novel syngeneic model of spontaneous HER2<sup>+ve</sup> breast cancer metastasisAadya Nagpal, Richard P Redvers, Xiawei Ling, et al.
The Lancet. Oncology|March 6, 2025
Timing of nivolumab with neoadjuvant carboplatin and paclitaxel for early triple-negative breast cancer (BCT1902/IBCSG 61-20; Neo-N): a non-comparative, open-label, randomised, phase 2 trialNicholas Zdenkowski, Marion J J Kuper-Hommel, Samuel M Niman, et al.
Nature Clinical Practice. Oncology|October 5, 2006
Gene signature evaluation as a prognostic tool: challenges in the design of the MINDACT trialJan Bogaerts, Fatima Cardoso, Marc Buyse, et al.
Oncotarget|September 12, 2015
Integrative proteomic and gene expression analysis identify potential biomarkers for adjuvant trastuzumab resistance: analysis from the Fin-her phase III randomized trialAmir Sonnenblick, Sylvain Brohée, Debora Fumagalli, et al.
Journal of the National Cancer Institute|April 4, 2026
The benefit of adjuvant pertuzumab and trastuzumab according to estrogen receptor and HER2 expression: a Sub-analysis of the APHINITY trialElisa Agostinetto, Gabriella Gentile, Faye Samy, et al.
Cancer Research|September 27, 2017
Combined CDK4/6 and PI3Kα Inhibition Is Synergistic and Immunogenic in Triple-Negative Breast CancerZhi Ling Teo, Stephanie Versaci, Sathana Dushyanthen, et al.
The Oncologist|July 3, 2016
Palbociclib in Combination With Fulvestrant in Women With Hormone Receptor-Positive/HER2-Negative Advanced Metastatic Breast Cancer: Detailed Safety Analysis From a Multicenter, Randomized, Placebo-Controlled, Phase III Study (PALOMA-3)Sunil Verma, Cynthia Huang Bartlett, Patrick Schnell, et al.
Endocrine-Related Cancer|May 15, 2014
Biology of breast cancer during pregnancy using genomic profilingHatem A Azim, Sylvain Brohée, Fedro A Peccatori, et al.
European Journal of Cancer (Oxford, England : 1990)|October 12, 2018
Predictors of prolonged benefit from palbociclib plus fulvestrant in women with endocrine-resistant hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer in PALOMA-3Massimo Cristofanilli, Angela DeMichele, Carla Giorgetti, et al.
Pageof 33

Showing results (131-140 of 325) with videos related to

Sort By:
Pageof 33
Cancer Research|September 1, 2017
CD73 Promotes Resistance to HER2/ErbB2 Antibody TherapyMartin Turcotte, David Allard, Deepak Mittal, et al.
Breast Cancer Research : BCR|August 15, 2019
Neoadjuvant neratinib promotes ferroptosis and inhibits brain metastasis in a novel syngeneic model of spontaneous HER2<sup>+ve</sup> breast cancer metastasisAadya Nagpal, Richard P Redvers, Xiawei Ling, et al.
The Lancet. Oncology|March 6, 2025
Timing of nivolumab with neoadjuvant carboplatin and paclitaxel for early triple-negative breast cancer (BCT1902/IBCSG 61-20; Neo-N): a non-comparative, open-label, randomised, phase 2 trialNicholas Zdenkowski, Marion J J Kuper-Hommel, Samuel M Niman, et al.
Nature Clinical Practice. Oncology|October 5, 2006
Gene signature evaluation as a prognostic tool: challenges in the design of the MINDACT trialJan Bogaerts, Fatima Cardoso, Marc Buyse, et al.
Oncotarget|September 12, 2015
Integrative proteomic and gene expression analysis identify potential biomarkers for adjuvant trastuzumab resistance: analysis from the Fin-her phase III randomized trialAmir Sonnenblick, Sylvain Brohée, Debora Fumagalli, et al.
Journal of the National Cancer Institute|April 4, 2026
The benefit of adjuvant pertuzumab and trastuzumab according to estrogen receptor and HER2 expression: a Sub-analysis of the APHINITY trialElisa Agostinetto, Gabriella Gentile, Faye Samy, et al.
Cancer Research|September 27, 2017
Combined CDK4/6 and PI3Kα Inhibition Is Synergistic and Immunogenic in Triple-Negative Breast CancerZhi Ling Teo, Stephanie Versaci, Sathana Dushyanthen, et al.
The Oncologist|July 3, 2016
Palbociclib in Combination With Fulvestrant in Women With Hormone Receptor-Positive/HER2-Negative Advanced Metastatic Breast Cancer: Detailed Safety Analysis From a Multicenter, Randomized, Placebo-Controlled, Phase III Study (PALOMA-3)Sunil Verma, Cynthia Huang Bartlett, Patrick Schnell, et al.
Endocrine-Related Cancer|May 15, 2014
Biology of breast cancer during pregnancy using genomic profilingHatem A Azim, Sylvain Brohée, Fedro A Peccatori, et al.
European Journal of Cancer (Oxford, England : 1990)|October 12, 2018
Predictors of prolonged benefit from palbociclib plus fulvestrant in women with endocrine-resistant hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer in PALOMA-3Massimo Cristofanilli, Angela DeMichele, Carla Giorgetti, et al.
Pageof 33